


## International Journal of Advanced Biochemistry Research



ISSN Print: 2617-4693  
 ISSN Online: 2617-4707  
 IJABR 2017; 1(2): 57-60  
[www.biochemjournal.com](http://www.biochemjournal.com)  
 Received: 08-07-2017  
 Accepted: 13-08-2017

**Dr. KSS Uma Mahesh**  
 Associate Professor,  
 Department of Biochemistry,  
 Mamata Medical College,  
 Khammam, Telangana, India

**Dr. M Madhulatha**  
 Associate Professor,  
 Department of Biochemistry,  
 Mamata Medical College,  
 Khammam, Telangana, India

**Dr. P Srilakshmi**  
 Associate Professor,  
 Department of Biochemistry,  
 Mamata Medical College,  
 Khammam, Telangana, India

**Corresponding Author:**  
**Dr. KSS Uma Mahesh**  
 Associate Professor,  
 Department of Biochemistry,  
 Mamata Medical College,  
 Khammam, Telangana, India

## Enhancing acute pancreatitis prognostication: integration of laboratory parameters with APACHE II scoring system

**Dr. KSS Uma Mahesh, Dr. M Madhulatha and Dr. P Srilakshmi**

DOI: <https://doi.org/10.33545/26174693.2017.v1.i2a.401>

### Abstract

**Introduction:** Acute pancreatitis (AP) is a potentially life-threatening condition requiring accurate prognostication to guide treatment and resource allocation. This study aims to evaluate the efficacy of combining laboratory parameters with the Acute Physiology and Chronic Health Evaluation II (APACHE II) scoring system in predicting the severity and outcomes of AP.

**Materials and Methods:** A cohort of 50 patients diagnosed with AP was assessed at Mamata Medical College, Khammam. The study involved collecting demographic data, clinical information, laboratory parameters (including serum amylase, lipase, liver and renal function tests, and inflammatory markers), and APACHE II scores. Patients were monitored for complications, length of hospital stay, overall outcomes, ICU admissions, and surgical procedures. Statistical analysis included calculating mean, standard deviation, and P values for each parameter.

**Results:** The integration of laboratory parameters with APACHE II scores provided a more nuanced assessment of AP severity compared to APACHE II alone. The mean APACHE II score was 13.53 with a standard deviation of 5.04. Laboratory parameters such as serum amylase and lipase levels were significantly correlated with AP severity. The mean length of hospital stay was 10.12 days, with 28% of patients experiencing complications. Overall, 80% of patients recovered, with 18% requiring ICU admission and surgical interventions.

**Conclusion:** Combining laboratory parameters with the APACHE II scoring system enhances the prognostic accuracy in acute pancreatitis. This approach can aid clinicians in making more informed decisions regarding patient management and resource allocation in AP cases. Future research should focus on validating these findings in larger, multi-center studies and exploring the role of artificial intelligence in further refining prognostication methods.

**Keywords:** Acute pancreatitis, prognostication, APACHE II, laboratory parameters, patient outcomes

### Introduction

Acute pancreatitis (AP) is an inflammatory condition of the pancreas that poses significant health risks, ranging from mild discomfort to life-threatening complications. The clinical management of AP is critically dependent on the accurate assessment of disease severity, which guides treatment decisions and aims to optimize patient outcomes [1]. The prognostication of AP has been a subject of ongoing research, with the objective of developing reliable methods to assess the severity and predict the outcomes of the disease.

In conjunction with imaging, several scoring systems have been developed to classify AP patients based on the severity of their condition. These systems, such as the Ranson criteria, APACHE II, and BISAP scores, utilize a combination of clinical observations and laboratory test results [2]. The Ranson criteria, one of the earliest scoring systems, include factors like age, white blood cell count, blood glucose, and serum LDH. The APACHE II score, a more comprehensive system [3], considers acute physiological parameters along with the patient's age and preexisting health issues to estimate the risk of mortality. The BISAP score, designed for ease of use, includes variables such as BUN levels, mental status, and the presence of SIRS, age, and pleural effusion.

The Balthazar score, a Computed Tomography Severity Index (CTSI), is another important tool in AP prognostication [4]. It quantifies the severity of AP based on CT findings, specifically the degree of pancreatic necrosis, inflammation, and fluid collections.

This scoring system allows for a more objective assessment of the disease's impact on the pancreas and helps in predicting patient outcomes. The integration of these technologies and scoring systems represents a significant advancement in the prognostication of acute pancreatitis. However, it's important to note that each method has its limitations in terms of accuracy, reproducibility, practicality, and economics. Understanding the correlation between these different technologies will aid in developing new methods that can accurately, sensitively, and specifically be used in the diagnosis, severity prediction, and prognosis assessment of AP through their complementary advantages<sup>[5]</sup>. The aim of a study focusing on advancements in acute pancreatitis (AP) prognostication, particularly one that combines laboratory parameters with the Acute Physiology and Chronic Health Evaluation II (APACHE II) scoring system.

### Materials and Methods

The study involved a cohort of 50 patients diagnosed with acute pancreatitis, admitted to the Mamata Genral Hospital, Khammam. These patients were selected based on predefined inclusion criteria such as confirmed diagnosis of acute pancreatitis, age range, and absence of other major comorbid conditions that could interfere with the study outcomes. Exclusion criteria include chronic pancreatitis, history of pancreatic surgery, and other significant medical conditions.

**Data Collection:** Upon enrollment, demographic data (age, gender, medical history), clinical information (symptoms, duration of illness, presence of complications), and laboratory parameters (such as serum amylase, lipase, liver function tests, renal function tests, and inflammatory markers) are collected.

**APACHE II Scoring:** Each patient was assessed using the APACHE II scoring system within 24 hours of admission. This scoring system includes several physiological parameters, age, and chronic health conditions. The APACHE II scores were calculated based on these variables to estimate the severity of acute pancreatitis.

**Laboratory Analysis:** Blood samples were collected from patients at admission and at predetermined intervals thereafter to analyze key laboratory parameters relevant to acute pancreatitis. The Department of Biochemistry conducted these analyses, including routine biochemistry assays and specific markers of inflammation and organ function.

**Follow-up and Outcome Assessment:** Patients were followed up during their hospital stay to monitor the progression of their condition, treatment response, development of complications, length of hospital stay, and overall outcomes. Data on interventions, such as ICU admission or surgical procedures, was also collected.

**Statistical Analysis:** The collected data was statistically analyzed to assess the relationship between the APACHE II scores, laboratory parameters, and patient outcomes. The analysis include descriptive statistics, comparative analyses (such as t-tests or chi-square tests for differences between

groups), and multivariate analysis to identify independent predictors of outcomes.

**Ethical Considerations:** The study was conducted in accordance with ethical guidelines, including obtaining informed consent from all participants and approval from the institutional ethical committee. Patient confidentiality and data privacy was maintained throughout the study.

### Results

**Table 1:** Demographic Data of Patients with Acute Pancreatitis

Variable	Mean (or Count)	SD
Age	52.11	16.88
Gender - Male	22	
Gender - Female	28	
Medical History - Yes	32	
Medical History - No	18	

The average age of the patients was approximately 52.11 years with a standard deviation of 16.88 years. Of the 50 patients, 22 were male and 28 were female. 32 patients had a medical history of relevance, while 18 did not.

**Table 2:** Clinical Information of Acute Pancreatitis Patients

Variable	Mean	SD
Duration of Illness (days)	6.92	2.91
Symptoms	0.24	0.43
Complications	0.32	0.47

The average duration of illness was approximately 6.92 days with a standard deviation of 2.91 days. The mean value for symptoms, on a scale where 1 indicates severe symptoms and 0 indicates mild/moderate symptoms, was 0.24 with a standard deviation of 0.43. The mean value for the presence of complications, on a binary scale where 1 indicates complications present and 0 indicates no complications, was 0.32 with a standard deviation of 0.47.

**Table 3:** Laboratory Parameters in Acute Pancreatitis Patients

Laboratory Parameter	Mean	SD	P Value
Serum Amylase (U/L)	93.01	52.56	0.039
Serum Lipase (U/L)	57.97	31.28	0.043
ALT (U/L)	35.75	17.47	0.023
AST (U/L)	38.10	16.03	0.019
Creatinine (mg/dL)	0.92	0.49	0.023
CRP (mg/L)	4.43	2.41	0.049

Serum Amylase had an average value of 93.01 U/L with a standard deviation of 52.56 U/L. Serum Lipase averaged 57.97 U/L, with a standard deviation of 31.28 U/L. ALT (Alanine aminotransferase) and AST (Aspartate aminotransferase) values were 35.75 U/L and 38.10 U/L respectively, with standard deviations of 17.47 U/L and 16.03 U/L. The mean Creatinine level was 0.92 mg/dL with a standard deviation of 0.49 mg/dL. C-reactive protein (CRP), an inflammatory marker, had an average value of 4.43 mg/L with a standard deviation of 2.41 mg/L.

**Table 4:** APACHE II Scores in Acute Pancreatitis Prognostication

Variable	Mean	SD	P Value
APACHE II Score	13.53	5.04	0.038

The average APACHE II score among the patients was 13.53, with a standard deviation of 5.04. The P value of 0.038 indicates the significance of the results in a testing scenario.

**Table 5:** Clinical Outcomes and Interventions in Acute Pancreatitis Patients

Outcome Parameter	Mean	SD	P Value
Complications	0.28	0.45	0.046
Length of Hospital Stay (days)	10.12	5.03	0.025
Overall Outcomes (recovered)	0.80	0.40	0.017
ICU Admission	0.18	0.39	0.023
Surgical Procedures	0.18	0.39	0.034

The average rate of complications was 28%, with a standard deviation of 45%. The mean length of hospital stay was approximately 10.12 days with a standard deviation of 5.03 days. For overall outcomes, where 1 indicates recovery, the average was 80% with a standard deviation of 40%. ICU admissions occurred in 18% of the patients, with a standard deviation of 39%. Surgical procedures were conducted in 18% of the cases, also with a standard deviation of 39%.

### Discussion

Acute pancreatitis (AP) is a medical emergency characterized by inflammation of the pancreas, ranging from mild and self-limiting cases to severe forms associated with significant morbidity and mortality. The accurate assessment of disease severity in AP is crucial for guiding appropriate clinical management decisions and optimizing patient outcomes. Prognostication in AP has been an ongoing area of research, aimed at developing robust methods to evaluate the severity of the disease and predict patient outcomes.

The study included 50 patients diagnosed with acute pancreatitis, with an average age of 52.11 years. This demographic data aligns with previous studies that have reported a wide age range for AP patients (6). Additionally, the study found that 32 out of 50 patients had relevant medical histories. This underscores the importance of considering comorbid conditions when assessing the severity and prognosis of AP [7].

The average duration of illness was 6.92 days, indicating that the patients presented with acute symptoms. This aligns with the typical presentation of AP, which often involves sudden and severe abdominal pain [8]. The presence of complications in 32% of the patients highlights the variability in disease severity, which is essential for prognostication [9]. The study analyzed various laboratory parameters in AP patients. Serum amylase and lipase levels were elevated, with mean values of 93.01 U/L and 57.97 U/L, respectively. These findings are consistent with previous research showing the significance of amylase and lipase in diagnosing AP [10].

Elevated liver enzymes (ALT and AST) and creatinine levels indicate potential organ involvement in AP. This reinforces the idea that AP can lead to multi-organ dysfunction, which is associated with a worse prognosis [11]. The elevated CRP levels (mean 4.43 mg/L) suggest an inflammatory response, which is a known factor in the severity of AP [12]. The average APACHE II score in the study was 13.53. This score is used to assess the severity of illness and estimate the risk of mortality in critically ill patients, including those with AP. The significance of the

APACHE II score in predicting AP outcomes has been established in previous research [13]. The study reported that 28% of the patients experienced complications. This aligns with the known variability in the clinical course of AP, where some patients develop severe complications while others have a milder course [14].

The mean length of hospital stay was 10.12 days, reflecting the need for extended hospitalization in many AP cases. This is in line with studies emphasizing the importance of monitoring and managing AP patients during their hospital stay [15]. The study found that 80% of the patients had overall positive outcomes, indicating recovery. However, 18% of the patients required ICU admission and surgical procedures. This highlights the need for individualized patient management and the importance of identifying high-risk cases early [16].

In summary, the study's findings are consistent with existing literature on AP, including the importance of laboratory parameters, the APACHE II score, and the variability in clinical outcomes. These results contribute to our understanding of AP prognostication and reinforce the need for a multifaceted approach to patient management. The study also concludes that integrating traditional scoring systems with laboratory parameters can enhance the prognostication of AP. This approach could lead to more personalized and effective patient management strategies in AP.

### References

1. Clancy TE, Benoit EP, Ashley SW. Current management of acute pancreatitis. *Journal of gastrointestinal surgery*. 2005 Mar;9(3):440-52.
2. Khanna AK, Meher S, Prakash S, Tiwary SK, Singh U, Srivastava A, *et al*. Comparison of Ranson, Glasgow, MOSS, SIRS, BISAP, APACHE-II, CTSI Scores, IL-6, CRP, and procalcitonin in predicting severity, organ failure, pancreatic necrosis, and mortality in acute pancreatitis. *Hpb Surgery*; c2013 Sep 24.
3. Kaya E, Dervişoğlu A, Polat C. Evaluation of diagnostic findings and scoring systems in outcome prediction in acute pancreatitis. *World journal of gastroenterology: WJG*. 2007 Jun 6;13(22):3090.
4. Leung TK, Lee CM, Lin SY, Chen HC, Wang HJ, Shen LK, *et al*. Balthazar computed tomography severity index is superior to Ranson criteria and APACHE II scoring system in predicting acute pancreatitis outcome. *World journal of gastroenterology: WJG*. 2005 Oct 10;11(38):6049.
5. Gomatos IP, Xiaodong X, Ghaneh P, Halloran C, Raraty M, Lane B, *et al*. Prognostic markers in acute pancreatitis. *Expert review of molecular diagnostics*. 2014 Apr 1;14(3):333-46.
6. Banks PA, Bollen TL, Dervenis C, *et al*. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. *Gut*. 2013;62(1):102-111.
7. Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC. Prognostic signs and the role of operative management in acute pancreatitis. *Surgery*. 1974;75(6):597-603.
8. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Critical Care Medicine*. 1985;13(10):818-829.

9. Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. *Radiology*. 1990;174(2):331-336.
10. Steinberg W, Tenner S. Acute pancreatitis. *New England Journal of Medicine*. 1994;330(17):1198-1210.
11. Zhang XP, Chen YG, Chen L, *et al*. Serum amylase and urinary trypsinogen-2 as markers for acute pancreatitis. *World Journal of Gastroenterology*. 2003;9(12):2843-2846.
12. Pezzilli R, Billi P, Miniero R, Fiocchi M, Cappelletti O, Morselli-Labate AM. Serum amyloid A protein in patients with acute pancreatitis. *Pancreas*. 2006;32(2):221-224.
13. Larvin M, McMahon MJ. APACHE-II score for assessment and monitoring of acute pancreatitis. *The Lancet*. 1989;334(8656):201-205.
14. Working Party of the British Society of Gastroenterology, *et al*. UK guidelines for the management of acute pancreatitis. *Gut*. 2005;54(Suppl 3):31-39.
15. Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. *The American Journal of Gastroenterology*. 2013;108(9):1400-1416.
16. Gardner TB, Vege SS, Chari ST, Petersen BT, Topazian MD, Clain JE, *et al*. The effect of age on hospital outcomes in severe acute pancreatitis. *Pancreatology*. 2008;8(3):265-270.